aTyr Pharma to Present at BIO CEO & Investor Digital Conference
09 févr. 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Presents Findings Further Validating NRP2 as a Potential Regulator of Solid Tumor Progression
25 janv. 2021 08h00 HE
|
aTyr Pharma, Inc.
Poster highlights NRP2 expression on immune cells in the tumor microenvironment. Company's lead NRP2 antibody, ATYR2810, is in development for oncology. SAN DIEGO, Jan. 25, 2021 ...
aTyr Pharma to Present Poster Highlighting Research Approach for Identifying Receptor Targets for Extracellular tRNA Synthetases
22 janv. 2021 08h00 HE
|
aTyr Pharma, Inc.
Poster to be presented at the 2021 Society for Laboratory Automation and Screening Digital International Conference and Exhibition. Research approach led to the identification of target receptors for...
aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Completes Subject Visits for Phase 1 Trial of ATYR1923 in Japan
14 janv. 2021 08h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Jan. 14, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
07 janv. 2021 07h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATYR1923 in COVID-19 Patients with Severe Respiratory Complications
04 janv. 2021 16h15 HE
|
aTyr Pharma, Inc.
Study met primary safety endpoint in moderate to severe hospitalized COVID-19 patients. A single dose of 3.0 mg/kg of ATYR1923 resulted in a median time to recovery of 5.5 days. 83% of patients...
aTyr Pharma Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of ATYR1923 in Patients with Pulmonary Sarcoidosis
21 déc. 2020 07h00 HE
|
aTyr Pharma, Inc.
SAN DIEGO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Third Quarter 2020 Results and Provides Corporate Update
12 nov. 2020 16h05 HE
|
aTyr Pharma, Inc.
Completes enrollment of ATYR1923 clinical trial in patients with COVID-19 severe respiratory complications. Topline data is expected at turn of calendar year. Announces Investigational New Drug...
aTyr Pharma Announces Publication in the Journal mAbs
11 nov. 2020 07h00 HE
|
aTyr Pharma, Inc.
Peer-reviewed paper supports aTyr’s antibody program. Research conducted in collaboration with AbCellera Biologics, Inc. SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:...
aTyr Pharma Announces Discovery of New Receptor Targets for Two tRNA Synthetases from its Pipeline
10 nov. 2020 07h00 HE
|
aTyr Pharma, Inc.
Discovery advances the understanding of extracellular tRNA synthetase pathways. Findings may contribute to the development of new therapeutics to treat cancer and fibrosis. SAN DIEGO, Nov. 10,...